OVERVIEW

From Pathways to PROs: Translating the Latest Evidence for Current and Emerging JAK Inhibitors to Clinical Practice is organized by CME Outfitters, LLC and will be held from Nov 20, 2018 - Nov 20, 2019.

Target Audience
Rheumatologists, primary care physicians, nurse practitioners, physician assistants, nurses, and pharmacists who treat patients with rheumatoid arthritis.

Credit Information:
CME Credit (Physicians):
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit (American Academy of PA's):
NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 credit. PAs should only claim credit commensurate with the extent of their participation.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal

Statement of Need
Current therapeutic approaches for RA rely on disease-modifying antirheumatic drugs (DMARDs) as well as on biologic therapeutics that target tumor necrosis factor (TNF), interleukin-6 (IL-6), and T cell activation or that eliminate CD20+ B cells. These treatments have limitations, such as waning efficacy over time, side effects, and dosing inconvenience. Clinicians need to be aware of what other treatment options exist or are emerging. Further, rheumatology clinicians often face challenges in translating clinical evidence and data to real-world practice, and assessing the role of patient-reported outcomes (PROs) is pertinent when determining the value of new therapeutics for RA.

This CME Outfitters enduring material, featuring expert faculty discussion and learner interactivity, will address gaps related to emerging discoveries of inflammatory targets, clinical trial data, and the role of patient-reported outcomes (PROs) in practice, with resources posted to the Rheumatology Digital Hub.

Learning Objectives:

At the end of this CE activity, participants should be able to:
• Translate basic clinical immunology to current evidence for the pathophysiology and MOA for current and emerging JAK inhibitors.
• Evaluate clinical trial data for emerging small molecule/intracellular signaling targets in the management of patients with rheumatoid arthritis.
• Assess the role of patient-reported outcomes (PROs) as measures for the value of new therapeutics for RA, in addition to safety and efficacy data.
The following learning objectives pertain only to those requesting CNE or CPE credit:
• Translate basic clinical immunology to current evidence for the pathophysiology and MOA for current and emerging JAK inhibitors.
• Evaluate clinical trial data for emerging small molecule/intracellular signaling targets in the management of patients with rheumatoid arthritis (RA).
• Assess the role of patient-reported outcomes (PROs) as measures for the value of new therapeutics for RA, in addition to safety and efficacy data.

Additional details will be posted as soon as they are available.